Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Coya Therapeutics, Inc.. The associated price target was raised to $16.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Thomas Shrader has given his Buy rating due to a combination of factors that highlight the potential of Coya Therapeutics, Inc. to make significant advancements in the treatment of ALS and FTD. The initiation of dosing in the ALSTARS trial for COYA-302 marks a critical milestone, with the trial designed to test the efficacy of combining CTLA-4 Ig and low dose IL2 in ALS patients. This approach is considered promising due to its potential to modulate the immune system and address the inflammatory nature of ALS, building on initial pilot study results that showed halted disease progression in patients.
Furthermore, Coya’s engagement with the FDA has been extensive, and the agency’s recognition of COYA-302 as a novel therapeutic rather than a mere combination of biosimilars underscores its potential. The ongoing trials, including the open-label study in FTD, have shown encouraging signs of cognitive stability in patients, which is significant given the expected decline in untreated individuals. With no safety issues reported thus far and a robust trial design, the company is well-positioned to advance its therapeutic candidates, supporting Shrader’s optimistic outlook and Buy rating.
According to TipRanks, Shrader is a 4-star analyst with an average return of 4.7% and a 39.34% success rate. Shrader covers the Healthcare sector, focusing on stocks such as NRX Pharmaceuticals, Harrow Health, and Vaxcyte.
In another report released on November 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.